Press Release – Page 12 – I-Mab | Pioneering the Next Generation of Immuno-Oncology

2021.06.01

I-Mab Appoints Ruyi He and Rong Shao to Board of Directors

2021.05.27

I-Mab Announces Upcoming Participation at June Conferences

2021.05.19

I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021

2021.05.18

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

2021.05.13

I-Mab Added to MSCI China Index

2021.04.28

I-Mab Filed 2020 Annual Report on Form 20-F

2021.04.26

I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis

2021.04.14

I-Mab Announces Selected Poster Presentation of CD73 Antibody Uliledlimab at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

2021.04.06

I-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors

2021.03.31

I-Mab Announces Upcoming Participation at April Conferences